A comparison of three different approaches to defining frailty in older patients with multiple myeloma

ConclusionIn a cohort of 40 older adults with newly diagnosed multiple myeloma, three frailty indices have differing approaches to operationalizing frailty resulting, in different patients being categorized as frail. Little agreement existed between the models. Further studies are needed to explore the utility of these models in predicting treatment toxicity and prognosis.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
WEDNESDAY, Aug. 21, 2019 -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say. A drug called selinexor appeared to help patients with...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Immunological aging is related to the development of cancer, but factors that impact this relationship are only partially understood. Several studies demonstrated that aging correlates with increased peripheral blood T lymphocyte (PBTL) expression of p16INK4a [1,2], a molecular marker associated with cellular senescence and irreversible cell cycle arrest [3]. PBTL p16INK4a levels not only increase with chronological age, but are influenced by physiologic stress caused by smoking, chemotherapy, and physical inactivity [3].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Blood Cancer Journal, Published online: 20 August 2019; doi:10.1038/s41408-019-0227-3Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
This article summarizes the milestones in the development of selinexor leading to this first approval for RRMM.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 7 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Deepu Madduri, Madhav V. Dhodapkar, Sagar Lonial, Sundar Jagannath, Hearn Jay ChoAbstractTherapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immunotherapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with the immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T-cell–directed strategies designed to promote cytotoxic activity a...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Papers Source Type: research
Blood Cancer Journal, Published online: 16 August 2019; doi:10.1038/s41408-019-0232-6Oprozomib in patients with newly diagnosed multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
lo Alberto Zaniboni The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequent risk of cancer. We included observational studies of adult subjects with previous exposure to antibiotics and available information on incident cancer diagnoses. For each of the eligible studies, data we...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Rockville-based CASI Pharmaceuticals Inc. has earned approval in China to market a cancer therapy — its first commercial product in its nearly three decades of existence. The biopharmaceutical company has received clearance from the China National Medical Products Administration, China’s regulatory agency for drugs and medical devices, to launch an injection treatment for patients with mult iple myeloma, a blood cancer that forms in infection-fighting plasma cells. It’s a major milestone for…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: Cancer | Cancer & Oncology | Geriatrics | Myeloma | Study | Toxicology